Impel NeuroPharma Inc. (IMPL) stock plunged at last close, followed by no current update.

Impel NeuroPharma Inc. (NASDAQ: IMPL) stock declined by 0.79% at the last close.  Impel NeuroPharma is a commercial-stage pharmaceutical firm focused on discovering innovative medicines for people suffering from illness with significant unmet medical needs, with a major emphasis on central nervous system ailments.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free

IMPL stock’ Past Development

On Nov 15, 2021, Impel announced its financial results for the third quarter of 2021. Given below are the highlights:

  • In the third quarter of 2021, R&D expenses were $5.9 million, compared to $6.1 million in the third quarter of 2020. The drop in R&D investment was mostly due to lower clinical costs for Trudhesa as the Phase 3 study came to an end.
  • SG&A expenses were $16.3 million in the third quarter of 2021, compared to $2.9 million in the third quarter of 2020. The rise in SG&A was primarily attributable to increased spending to support commercial and marketing preparations for the Trudhesa launch.
  • Impel recorded a net loss of $25.0 million in Q3 of 2021, whereas the net loss was $9.2 million in the third quarter of 2020.
  • In the third quarter of 2021, GAAP Net Loss per Share was $1.24 per share, compared to $15.56 in the third quarter of 2020.
  • In the third quarter of 2021, non-GAAP Net Loss per Share was $1.23, compared to $0.49 in the third quarter of 2020.
  • The company had $111.3 million in cash and cash equivalents as of September 30, 2021.

Adrian Adams, Chairman and CEO of Impel NeuroPharma commented that,

The third quarter was genuinely transformative for Impel, with the licensing and timely release of Trudhesa. Since their commercial release in early October, they’ve been ecstatic with the early uptake and prescription trends they’ve seen in the market. They are convinced that Impel’s improved balance sheet will give them the funds they need to maintain the successful commercialization of Trudhesa given the recent follow-on equity offering. It will also aid in the development of INP105 for the cure of agitation and violence in people with autism.


On What Basis Did Swvl Holdings Corp (SWVL) Stock Rise 47% Pre-Hours?

When last checked, Swvl Holdings Corp. (Nasdaq: SWVL), a...

What Drove Organovo (ONVO) Stock Up 15% In After-Hour Session On Tuesday?

Shares of Organovo Holdings Inc. (Nasdaq: ONVO) were up...

Is There Any Reason As To Why The Zai Lab (ZLAB) Stock Expanded By 13%?

The biopharmaceutical business Zai Lab Limited (NASDAQ: ZLAB), which...



Don't miss

Wearable Devices (WLDS) Stock Rose 12% On Tuesday, But On What Basis?

Wearable Devices Ltd (NASD: WLDS) is experiencing significant growth...

Did Anything Boost ObsEva (OBSV) Stock In Pre-Hours Trading?

Following an update, shares of ObsEva SA (NASD: OBSV)...

How Did The Kalera (KAL) Stock Rise 32% Pre-Hours?

At the time of the most recent check, shares...

Why Has Selina Hospitality (SLNA) Stock Increased In Extended Session On Friday?

The stock of Selina Hospitality PLC (NASD: SLNA), which...

A look at Community Health Systems Inc.’s (CYH) recent performance gives investors their first glimpse of hope.

Community Health Systems Inc. (NYSE: CYH) on September 29, 2023, started off the session at the price of $2.84, soaring 5.45% from the previous...

Investors finally get a glimpse of Viasat Inc. (VSAT) volume hitting the figure of 1.41 million.

September 29, 2023, Viasat Inc. (NASDAQ: VSAT) trading session started at the price of $18.40, that was 1.37% jump from the session before. During...

Gatos Silver Inc (GATO) volume exceeds 1.57 million: A new investment opportunity for investors

On September 29, 2023, Gatos Silver Inc (NYSE: GATO) opened at $5.28, higher 0.78% from the last session. During the day, the shares moved...


Please enter your comment!
Please enter your name here